BRAF and melanoma: To examine the impact of PI3K/AKT signalling on melanoma responses to BRAF/MEK inhibition, MM200 and SKMel28 cells expressing oncogenic PIK3CA or AKT3 mutants were treated with BRAF and MEK inhibitors.